Weill Cornell Medicine and Roswell Park Comprehensive Cancer Center reported preclinical results for intravesical CAR T therapy targeting MUC16 in bladder cancer. In a Journal of Experimental Medicine paper, investigators led by Taha Merghoub, PhD engineered catheter-delivered CAR T cells designed to kill bladder cancer cells directly inside the bladder. In mouse models, the intravesical delivery approach controlled bladder tumors and established MUC16 as a clinically relevant target for anti-bladder-cancer CAR T strategies. The team positioned the catheter-based route as a potential way to reduce hurdles typical of solid-tumor CAR T programs, where limited infiltration and off-target toxicity often limit efficacy. The immediate translational implication is route-of-administration focus: if the approach can be replicated safely in humans, it could widen the set of “solid tumor-ready” CAR T strategies beyond purely systemic delivery models.